A study recently published in Health and Quality of Life Outcomes analyzed quality of life in patients with pulmonary arterial hypertension (PAH).
PAH is a rare condition affecting the heart and lungs. It is characterized by abnormally high blood pressure (hypertension) in the pulmonary artery. Symptoms include shortness of breath during exercise and fainting spells. The symptoms tend to get worse over time and may include dizziness, edema of the ankles or legs, chest pain, and a racing pulse. Some cases of PAH are due to genetic changes in the BMPR2 gene. It can also occur secondary to underlying conditions such as connective tissue diseases, HIV infection, chronic hemolytic anemia, and congenital heart disease, or be induced by certain drugs and toxins.
Patients with PAH experience a significant impact on their quality of life. This study assessed and synthesized the evidence on the impact of PAH on a patient’s quality of life as measured by patient-reported outcome measures.
A systematic review of 44 studies that met inclusion criteria was conducted following PRISMA guidelines. Patient-reported outcome measures included SF-36, SF-12, CAMPHOR (Cambridge Pulmonary Hypertension Outcome Review), EQ-5D, and EmPHasis-10.
Results indicated a contrast in quality of life outcomes, highlighting significant physical impairment and relatively preserved mental health scores.Subgroup analyses also indicated notable heterogeneity, emphasizing the need for standardized tools in quality of life assessment.
This assessment emphasizes the importance of patient-reported outcome measures in understanding quality of life in patients with PAH. The study suggests these be integrated in clinical assessments and standardizing methodologies.
To learn more about PAH and other rare heart conditions, visit https://checkrare.com/diseases/heart-diseases/
